VASTRA FROLUNDA, Sweden--(BUSINESS WIRE)--Regulatory News:
The biomaterials company Artimplant (STO:ARTIB) has received regulatory clearance for marketing Artelon® Tissue Reinforcement for new indications in the USA. The new clearance offers the opportunity to reach a considerably larger market.
Since 2006 it has been possible to market Artelon® Tissue Reinforcement in the USA as reinforcement of soft tissue tears in the shoulder, limited to the supraspinatus tendon. The present regulatory clearance provides Artimplant and its licensee, Biomet Sports Medicine, with the opportunity to market the product for general soft tissue repair. Examples of new indications that can be marketed are general reinforcement of the rotator cuff in the shoulder and tendon repair around the kneecap, biceps, front thigh muscle (quadriceps) and Achilles tendon.
